How many insider trades does FilingIQ track for ABCL?

FilingIQ tracks 107 Form 4 insider transactions for ABCL (AbCellera Biologics Inc.), covering filings from Dec 17, 2020 onwards. 5 of those are dated within the last 90 days.

Are ABCL insiders net buyers or net sellers?

Across the full Form 4 history for ABCL, 45 transactions (42%) were open-market purchases and 10 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ABCL insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is ABCL in?

AbCellera Biologics Inc. (ABCL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.04B.

ABCL insider trading

NasdaqGS Healthcare

AbCellera Biologics Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

107

Last 90 days

Buys / sells

42% / 9%

Market cap

$1.04B

About AbCellera Biologics Inc.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Company website: www.abcellera.com

ABCL insider activity at a glance

FilingIQ tracks 107 insider transactions for ABCL in filings since Dec 17, 2020. The most recent transaction is dated Aug 24, 2026.

Across the full history, 45 open-market purchases and 10 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ABCL insider trades is 54.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ABCL trades on FilingIQ Raw filings on SEC EDGAR

Latest ABCL Form 4 filings

Booth Andrew Chief Financial Officer

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

13F funds holding ABCL

BAKER BROS. ADVISORS LP

$259.15M · 1.3% of AUM

Frequently asked

How many insider trades does FilingIQ track for ABCL?: FilingIQ tracks 107 Form 4 insider transactions for ABCL (AbCellera Biologics Inc.), covering filings from Dec 17, 2020 onwards. 5 of those are dated within the last 90 days.
Are ABCL insiders net buyers or net sellers?: Across the full Form 4 history for ABCL, 45 transactions (42%) were open-market purchases and 10 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ABCL insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is ABCL in?: AbCellera Biologics Inc. (ABCL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.04B.

Methodology & sources

Every ABCL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.